^
    2d
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Peking University Third Hospital
    New trial
    |
    Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
    9d
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (clinicaltrials.gov)
    P2, N=79, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Jun 2025 --> Dec 2025
    Trial initiation date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)
    9d
    Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    1m
    Clinical Study on the Efficacy and Safety of Orelabrutinib Consolidation and Maintenance Therapy in Patients with Previously Untreated Marginal Zone Lymphoma (ChiCTR2500110878)
    P2, N=23, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    2ms
    Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL (clinicaltrials.gov)
    P2, N=169, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib) • bendamustine
    2ms
    ADAPT-MCL: Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Inokai (orelabrutinib) • bendamustine
    2ms
    Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Zhengzhou University
    New trial
    |
    Tyvyt (sintilimab) • Inokai (orelabrutinib) • Carteyva (relmacabtagene autoleucel)
    2ms
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment (clinicaltrials.gov)
    P2, N=45, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • cytarabine • etoposide IV • Inokai (orelabrutinib) • carmustine • melphalan
    2ms
    A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, Ruijin Hospital
    New trial
    |
    temozolomide • Xpovio (selinexor) • Inokai (orelabrutinib) • thiotepa
    2ms
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (clinicaltrials.gov)
    P2/3, N=215, Not yet recruiting, Huashan Hospital
    New P2/3 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • Vumon (teniposide)
    3ms
    Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma. (PubMed, Front Immunol)
    Cytokines such as IL-6, IL-8, and IL-10 levels were also substantially lowered in these patients. Orelabrutinib, lenalidomide plus sintilimab demonstrated promising efficacy and a manageable safety profile in Chinese patients with R/R DLBCL.
    Clinical data • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CRP (C-reactive protein)
    |
    lenalidomide • Tyvyt (sintilimab) • Inokai (orelabrutinib)
    3ms
    New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen (clinicaltrials.gov)
    P=N/A, N=136, Completed, Huashan Hospital | Active, not recruiting --> Completed | N=80 --> 136
    Trial completion • Enrollment change
    |
    Inokai (orelabrutinib)